{"schema_version":"secwatch.filing_event.v1","accession":"0000950103-25-013103","form_type":"8-K","ticker":"ADCT","cik":"0001771910","company_name":"ADC Therapeutics SA","filed_at":"2025-10-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.385208+00:00","generated_at":"2026-05-17T03:56:57.297472+00:00","sec_items":["1.01","2.02","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ADC Therapeutics raises $60M PIPE; prelim Q3 ZYNLONTA revenue $15.8M, cash $234.7M","bullets":["PIPE of 11.25M shares at $4.00 and 3.85M pre-funded warrants at $3.90; gross $60M, close expected Oct 27.","Preliminary Q3 2025 ZYNLONTA net product revenue approximately $15.8M.","Cash and equivalents $234.7M as of Sep 30; pro forma $292.3M after PIPE net proceeds (~$57.6M).","PIPE led by TCGX with Redmile Group and other existing investors; Jefferies acted as placement agent.","Net proceeds to fund ZYNLONTA commercial expansion, strengthen balance sheet, and working capital."],"urls":{"canonical":"https://secwatch.observer/filing/0000950103-25-013103","json":"https://secwatch.observer/filing/0000950103-25-013103.json","markdown":"https://secwatch.observer/filing/0000950103-25-013103.md","text":"https://secwatch.observer/filing/0000950103-25-013103.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1771910/000095010325013103/0000950103-25-013103-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1771910/000095010325013103/dp235779_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:56:57.297472+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}